Results 241 to 250 of about 389,869 (294)

Complications Leading to Death in Patients Supported by the Impella 5.5: Analysis From the FDA MAUDE Database

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background The Impella 5.5 is increasingly being used in patients with cardiogenic shock, but experience with the device remains limited, and severe complications, including death, have been reported. This study aims to investigate causes of Impella 5.5‐related deaths.
Omar Khalil, Hussein Krayem, Aditya Kesari, Arun U. Mahtani, Matthew G. Kaye, Charlotte Roberts, Inna Tchoukina, Melissa C. Smallfield, Josue Chery, Zubair A. Hashmi, Michael C. Kontos, Keyur B. Shah, Pengyang Li   +12 more
wiley   +1 more source

Heart transplantation in South America: Risk factors, challenges, and opportunities. [PDF]

JHLT Open
Loyaga-Rendon RY, Acharya D.
europepmc   +1 more source

Pressure‐Wire Guided Hybrid Branch Pulmonary Artery Band Placement for Palliation of Single Ventricle and Critical Congenital Cardiac Lesions

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Historically, bilateral pulmonary artery band (PAB) placement was guided by pulmonary blood flow surrogates including systemic blood pressure (BP) and arterial saturation. These metrics alone may result in suboptimal bPAB placement.
Jonathan Pacella, Bryan H. Goldstein, Eiméar McGovern, Shabana Shahanavaz, Russel Hirsch, David Lehenbauer, David Winlaw, David L. S. Morales, Sarosh P. Batlivala   +8 more
wiley   +1 more source

Tricuspid Regurgitation after Orthotopic Heart Transplantation: Trajectories and Association With Mortality. [PDF]

Clin Transplant
Belani K, Brinker V, Fuller M, Cooter M, Schroder JN, Mamoun N, DeVore A, Swaminathan M, Nicoara A, McCartney SL.   +9 more
europepmc   +1 more source

Coronary Artery Vasculopathy in a Cohort of Heart Transplant Recipients: A Single Center Experience

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Coronary allograft vasculopathy (CAV) is a significant cause of late mortality in heart transplant recipients. This study assesses the development of CAV, associated rejection rates, and the potential impact of percutaneous coronary intervention (PCI) on survival in a cohort of heart transplant patients.
Hussein Krayem, Omar Khalil, Nayef Abouzaki, Richard Cooke, Issa Kutkut   +4 more
wiley   +1 more source

Redefining Primary Graft Dysfunction: Toward a Consensus in the New Era of Heart Transplantation. [PDF]

Transplantation
Leon M, Shudo Y.
europepmc   +1 more source

FAILURE OF SINO-ATRIAL NODAL TRANSPLANTATION FOR THE TREATMENT OF EXPERIMENTAL COMPLETE HEART BLOCK IN DOGS. [PDF]

, 1963
AXTELL, HK, HERMANN, G, MARCHIORO, TL, STARZL, TE, WADDELL, WR   +4 more
core  

Contemporary Perspectives on Chronic Renal Disorders

Chronic Diseases and Translational Medicine, EarlyView.
ABSTRACT The prevalence of renal diseases and its associated burden on healthcare have tremendously risen in the past few years. From simple markers assessing kidney function, current renal research delves into understanding the diseases at the cellular and molecular levels and not just at treating, but at improving quality of life, arresting ...
Deenadhayalan Ashok, Poornima Ajay Manjrekar, Bhushan C. Shetty, Sujina S. S, Rukmini Mysore Srikantiah, Sowndarya Kollampare   +5 more
wiley   +1 more source

Heart transplantation in controlled donation after circulatory determination of death: the Italian experience. [PDF]

Ann Cardiothorac Surg
Boffini M, Gerosa G, Luciani GB, Pacini D, Russo CF, Rinaldi M, Terzi A, Pelenghi S, Luzi G, Zanatta P, Zanierato M, Sacchi M, Bottazzi A, Tarzia V, Onorati F, Pellegrini C, Suarez SM, Mondino M, Lilla Della Monica P, Nanni A, Marro M, Oliveti A, Feltrin G, Cardillo M.   +23 more
europepmc   +1 more source

First‐in‐Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN‐3143, a Novel Inhibitor of Mono‐Adenosine Diphosphate Ribosyltransferase‐PARP14

Clinical Pharmacology in Drug Development, EarlyView.
Abstract RBN‐3143 is an inhibitor of PARP14 in development for inflammatory diseases. Multiple assessments were conducted to evaluate the clinical pharmacology properties of RBN‐3134. A randomized, double‐blind, placebo‐controlled study assigned healthy volunteers (HVs) to single ascending doses (SADs) (25‐1000 mg) or multiple ascending doses (MADs ...
Thomas M. Polasek, Alexandra Cole, Viviana Bozón, Erika Manyak, Jonathan Novak, Barbara Yang, Briohny A. Johnston, Sudha Parasuraman, Kushal J. Paneliya, Virna Schuck   +9 more
wiley   +1 more source